Biogen is looking for a new CEO less than a year after the launch of its Alzheimer’s drug largely fizzled. The company said Tuesday that current CEO Michel Vounatsos will continue to lead the company until a successor is found. Aduhelm was the first new Alzheimer’s drug introduction in nearly two decades. Initially priced at $56,000 a year, it was expected to quickly become a blockbuster drug that would generate billions for Biogen. The Cambridge, Massachusetts, company has since slashed the price in half — to $28,000 a year — and Aduhelm’s rollout has been disastrous. The federal government imposed tight Medicare coverage restrictions on the drug, which brought in $2.8 million in sales in
Hence then, the article about change at the top at biogen after struggles with aduhelm was published today ( ) and is available onChron ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Change at the top at Biogen after struggles with Aduhelm )